ArticleMovement disorders clinical practice2025
Micrographia in Parkinson's Disease: Automatic Recognition through Artificial Intelligence.
Article in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Digital Handwriting Reveals Motor Impairment, Dopaminergic Response, and Progression in Parkinson's Disease.Movement disorders clinical practice · 2026Article
- Progressive micrographia in Parkinson's disease is associated with multidimensional cognitive and motor features.Journal of neural transmission (Vienna, Austria : 1996) · 2026Article
- GLP-1 agonists in neurodegeneration: a multimodal biomarker-guided approach.Trends in molecular medicine · 2026Review
- The Effect of Data Leakage and Feature Selection on Machine Learning Performance for Early Parkinson's Disease Detection.Bioengineering (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundParkinson's disease (PD) leads to handwriting abnormalities primarily characterized by micrographia. Whether micrographia manifests early in PD, worsens throughout the disease, and lastly responds to L-Dopa is still under scientific debate.
objectivesWe investigated the onset, progression and L-Dopa responsiveness of micrographia in PD, by applying a non-invasive and cheap tool of artificial intelligence- (AI)-based pen-and-paper handwriting analysis.
methodsFifty-seven PD undergoing chronic L-Dopa treatment were enrolled, including 30 early-stage (H&Y ≤ 2) and 27 mid-advanced stage (H&Y > 2) patients, alongside 25 age- and sex-matched controls. Participants completed two standardized pen-and-paper handwriting tasks in an ecological scenario. Handwriting samples were examined through clinically-based (ie, perceptual) and AI-based (ie, automatic) procedures. Both consistent (ie, average stroke size) and progressive (ie, sequential changes in stroke size) micrographia were evaluated. Receiver operating characteristic (ROC) curves were used to evaluate the accuracy of the convolutional neural network (CNN) in classifying handwriting in PD and controls.
resultsClinically- and AI-based analysis revealed a general reduction in stroke size in PD supporting the concept of parkinsonian micrographia. Compared with perceptual analysis, AI-based analysis clarified that micrographia manifests early during the disease, progressively worsens and poorly responds to L-Dopa. The AI models achieved high accuracy in distinguishing PD patients from controls (91%), and moderate accuracy in differentiating early from mid-advanced PD (77%). Lastly, the AI model was not able to detect patients in OFF and ON states.
conclusionsAI-based handwriting analysis is a valuable non-invasive and cheap tool for detecting and quantifying micrographia in PD, for telemedicine purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.